Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

June 18, 2022 by Alan Khadavi

Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis

Roflumilast and Tapinarof are 2 emerging topical therapies that have completed or have ongoing phase 3 clinical trials, with the possibility of approval in 2022.

Roflumilast is a more potent PDE4 inhibitor than crisaborloe (Eucrisa) with fewer local reactions.

Tapinarof, the first therapeutic arylhydocarbon modulating agent for which the only associated local effect is noninfectious folliculitis/follicular plugging with perifolliclular inflammation.

The last few years have brought on many new therapies for atopic dermatitis/eczema. For many year, the only treatment available was topical steroid medications. Which many patients avoided because of side effects. Elidel and Protopic were 2 medications that emerged after many years, but their efficacy was limited.

The last few years have seen 2 new topical therapies, Eucrisa and Opzeluara.

Eucrisa (crisaborole) New Eczema Medication gets FDA Approval

Opzelura (ruxolitinib) for Eczema

Two need injectable medications have also come out very recently and they are both used to treat moderate to severe eczema.

Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers

Adbry Tralokinumab for Atopic Dermatitis

Most recently a new class of oral medications have come out called the JAK inhibitors, there are currently 2 available in this category.

Upadacitinib for Atopic Dermatitis (Eczema)

Cibinqo Abrocitinib for Atopic Dermatitis by Pfizer

Topical Roflumilast, is a PDE4 inhibitor, it increases cyclic AMP and inhibits proinflammatory cytokine release. It is a 0.15% cream for mild to moderate atopic dermatitis in trials. It is a nonsteroidal agent, it improves itch and inflammation. It is safe and effective for delicate areas (eg face), given it does not cause atrophy. There is no known ocular toxicity. Side effects are local irritation (and stinging/burning) are uncommon. Adverse effects to suggest systemic absorption of PDE4 inhibitor (nausea and diarrhea) are rare, (<1%). It is currently being studied for ages 2 and up.

Topical Tapinarof, is a therapeutic aryl hydrocarbon modulating agent. It agonizes keratinocyte aryl hydrocarbon receptor and also inhibits artemin and its stimulation of TRPV1 receptors on neurons. It is a 1% cream for moderate to severe atopic dermatitis in adults. It is non-steroidal and reports show an improvement in inflammation and itch. Only known adverse event is local folliculitis. Its being studied for 2 and up as well.

In conclusion, the treatment of eczema should start with topical steroids combined with nonsteroidal topical agents. These medications start the foundation for treatment. Then it is tailored on an individual basis while trying to avoid triggers and managing comorbid diagnoses. Systemic agents are next in line, but with the emerging availability of more targeted treatment such as roflumilast and tapinarof, systemic therapy may not be needed as much to achieve long term control and improve quality of life.

New treatments for eczema on the horizon

Treatment of Atopic Dermatitis (Eczema)

Common Eczema Triggers

 

Filed Under: atopic dermatitis, Blog, Medications, Uncategorized

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

July 5, 2022

Itepekimab (Anti IL-33) & Brodalumab (Anti IL-25) for Asthma

Itepekimab and Brodalumab

June 18, 2022

Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis

roflumilast tapinarof

June 9, 2022

Avocado Allergy Comes in Many Flavors

avocado allergy

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

April 19, 2022

Fasenra for Nasal Polyps, a new treatment option

fasenra for nasal polyps

April 19, 2022

Asivatrep a new topical treatment for Eczema

asivatrep cream

April 3, 2022

Kiwi Allergy can come in many flavors

Kiwi allergy

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page